## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.6% below STRENGTH zone (3.0-6.0%); RSI 77 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (77).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones**
- Source: Insider Monkey | 20260102T144809 | Bullish | Relevance: 100%
- Viatris Inc. (NASDAQ: VTRS) announced four recent regulatory milestones including FDA approval for octreotide acetate (a generic version of SandostatinÂ® LAR Depot), FDA acceptance of a New Drug Application for a low-dose estrogen weekly patch for contraception, and FDA clearance for an Investigational New Drug application for MR-146 for neurotrophic keratopathy. Additionally, the Japan PMDA accepted a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company is a global healthcare provider with products across various therapeutic areas.

**2. Viatris stock hits 52-week high at $12.60**
- Source: Investing.com India | 20251231T160828 | Bullish | Relevance: 100%
- Viatris Inc. (VTRS) stock reached a new 52-week high of $12.60, marking a 5.84% increase over the past year and a 43.67% gain over six months. The pharmaceutical company exhibits solid financial health with a 3.83% dividend yield and a 12% free cash flow yield, with InvestingPro analysis suggesting it is undervalued and management is actively buying back shares. This milestone comes alongside recent positive Q3 2025 earnings, surpassing analyst expectations, and significant regulatory approvals.

**3. Viatris stock hits 52-week high at $12.60**
- Source: Investing.com | 20251231T155306 | Bullish | Relevance: 100%
- Viatris Inc. (VTRS) stock reached a new 52-week high of $12.60, reflecting a 5.84% increase over the past year and a 43.67% gain over the last six months. The pharmaceutical company demonstrates solid financial health with a 3.83% dividend yield and a 12% free cash flow yield, and InvestingPro analysis suggests it is undervalued with active share buybacks. Despite the stock being in overbought territory according to the RSI, recent Q3 2025 earnings surpassed analyst expectations, and the company achieved significant regulatory milestones.

**4. US FDA approves Vanda Pharmaceuticals' motion sickness drug**
- Source: Reuters | 20251231T205800 | Neutral | Relevance: 64%
- The U.S. FDA has approved Vanda Pharmaceuticals' drug Nereus (tradipitant) for motion-induced vomiting, marking the first new treatment for the condition in over 40 years. The company anticipates launching the drug in the coming months, with analysts projecting over $100 million in annual sales in the U.S. alone. This approval follows the FDA lifting a partial clinical hold after reclassifying motion sickness as an acute condition.

**5. Delek Shares Surge 60% but One Fund Walked Away From a $15 Million Position**
- Source: The Globe and Mail | 20260101T000906 | Neutral | Relevance: 61%
- Boston-based Callodine Capital Management fully liquidated its $15.19 million position in Delek US Holdings (NYSE:DK) during the third quarter, selling 717,245 shares. This decision came despite Delek shares surging 60% over the past year, outperforming the S&P 500. The fund's move suggests a strategy of locking in gains and a preference for less capital-intensive and cyclical investments than Delek, an integrated downstream energy company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.07 indicates undervaluation relative to growth. Forward P/E 5.1x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.4B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.62 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.07 |
| Forward P/E | 5.1 |
| Current P/E | 5.4 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.6% (minimal 5-day change). Below STRENGTH zone by 0.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 77, risk of mean reversion. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.56% (CS: 81) | Neutral |
| RSI_14 | 76.6 | Overbought |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.129x | Above |
| vs SMA200 | 1.290x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $12.46
- **Stop Loss:** $11.90 (4.5% risk)
- **Target:** $13.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2571
- **Position Value:** $32,034.66
- **Portfolio %:** 32.03%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*